Skip to main content
Top
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

ROCK1 as a novel prognostic marker in vulvar cancer

Authors: Erica M Akagi, André M Lavorato-Rocha, Beatriz de Melo Maia, Iara S Rodrigues, Kátia C Carvalho, Monica M Stiepcich, Glauco Baiocchi, Yukie Sato-Kuwabara, Silvia R Rogatto, Fernando A Soares, Rafael M Rocha

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Vulvar carcinoma is an infrequent tumour, accounting for fewer than 3% of all malignant tumours that affect women, but its incidence is rising in the past few decades. In young women, the manifestation of the vulvar carcinoma is often linked to risk factors such as smoking and HPV infection, but most cases develop in women aged over 50 years through poorly understood genetic mechanisms. Rho-associated coiled-coil-containing protein kinase 1 (ROCK1) has been implicated in many cellular processes, but its function in vulvar cancer has never been examined. In this study, we aimed to determine the prognostic value of ROCK1 gene and protein analysis in vulvar squamous cell carcinoma (VSCC).

Methods

ROCK1 expression levels were measured in 16 vulvar tumour samples and adjacent normal tissue by qRT-PCR. Further, 96 VSCC samples were examined by immunohistochemistry (IHC) to confirm the involvement of ROCK1 in the disease. The molecular and pathological results were correlated with the clinical data of the patients. Sixteen fresh VSCC samples were analyzed by array-based comparative genomic hybridization (aCGH).

Results

In each pair of samples, ROCK1 levels were higher by qRT-PCR in normal tissue compared with the tumour samples (p = 0.016). By IHC, 100% of invasive front areas of the tumour and 95.8% of central tumour areas were positive for ROCK1. Greater expression of ROCK1 was associated with the absence of lymph node metastasis (p = 0.022) and a lower depth of invasion (p = 0.002). In addition, higher ROCK1 levels correlated with greater recurrence-free survival (p = 0.001). Loss of ROCK1 was independently linked to worse cancer-specific survival (p = 0.0054) by multivariate analysis. This finding was validated by IHC, which demonstrated enhanced protein expression in normal versus tumour tissue (p < 0.001). By aCGH, 42.9% of samples showed a gain in copy number of the ROCK1 gene.

Conclusions

ROCK1 is lower expressed in tumour tissue when compared with adjacent normal vulvar epithelia. In an independent sample set of VSCCs, lower expression levels of ROCK1 correlated with worse survival rates and a poor prognosis. These findings provide important information for the clinical management of vulvar cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference De Melo MB, Munhoz Cestari F, Lavorato-Rocha AM, Sant’Ana Rodrigues I, Baiocchi G, Cardoso Guimarães G, Vassallo J, Stiepcich M, Soares FA, Malagoli Rocha R: Characterization of sociodemographic and clinicopathological features in Brazilian patients with vulvar squamous cell carcinoma. Gynecol Obstet Invest. 2013, 75 (1): 53-60. 10.1159/000343758.CrossRef De Melo MB, Munhoz Cestari F, Lavorato-Rocha AM, Sant’Ana Rodrigues I, Baiocchi G, Cardoso Guimarães G, Vassallo J, Stiepcich M, Soares FA, Malagoli Rocha R: Characterization of sociodemographic and clinicopathological features in Brazilian patients with vulvar squamous cell carcinoma. Gynecol Obstet Invest. 2013, 75 (1): 53-60. 10.1159/000343758.CrossRef
2.
go back to reference Lavorato-Rocha AM, De Melo Maia B, Rodrigues IS, Stiepcich MM, Baiocchi G, Da Silva Cestari FM, Carvalho KC, Soares FA, Rocha RM: Prognostication of vulvar cancer based on p14ARF status: molecular assessment of transcript and protein. Ann Surg Oncol. 2013, 20 (1): 31-39. 10.1245/s10434-012-2560-7.CrossRefPubMed Lavorato-Rocha AM, De Melo Maia B, Rodrigues IS, Stiepcich MM, Baiocchi G, Da Silva Cestari FM, Carvalho KC, Soares FA, Rocha RM: Prognostication of vulvar cancer based on p14ARF status: molecular assessment of transcript and protein. Ann Surg Oncol. 2013, 20 (1): 31-39. 10.1245/s10434-012-2560-7.CrossRefPubMed
3.
go back to reference Trietsch MD, Peters AA, Gaarenstroom KN, Van Koningsbrugge SH, Ter Haar NT, Osse EM, Halbesma N, Fleuren GJ: Spindle cell morphology is related to poor prognosis in vulvar squamous cell carcinoma. Br J Cancer. 2013, 109 (8): 2259-2265. 10.1038/bjc.2013.563.CrossRefPubMedPubMedCentral Trietsch MD, Peters AA, Gaarenstroom KN, Van Koningsbrugge SH, Ter Haar NT, Osse EM, Halbesma N, Fleuren GJ: Spindle cell morphology is related to poor prognosis in vulvar squamous cell carcinoma. Br J Cancer. 2013, 109 (8): 2259-2265. 10.1038/bjc.2013.563.CrossRefPubMedPubMedCentral
4.
go back to reference Del Pino M, Rodriguez-Carunchio L, Ordi J: Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma. Histopathology. 2013, 62 (1): 161-175. 10.1111/his.12034.CrossRefPubMed Del Pino M, Rodriguez-Carunchio L, Ordi J: Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma. Histopathology. 2013, 62 (1): 161-175. 10.1111/his.12034.CrossRefPubMed
5.
go back to reference De Melo MB, Lavorato-Rocha AM, Rodrigues IS, Baiocchi G, Cestari FM, Stiepcich MM, Chinen LT, Carvalho KC, Soares FA, Rocha RM: Prognostic significance of c-KIT in vulvar cancer: bringing this molecular marker from bench to bedside. J Transl Med. 2012, 10: 150-10.1186/1479-5876-10-150.CrossRef De Melo MB, Lavorato-Rocha AM, Rodrigues IS, Baiocchi G, Cestari FM, Stiepcich MM, Chinen LT, Carvalho KC, Soares FA, Rocha RM: Prognostic significance of c-KIT in vulvar cancer: bringing this molecular marker from bench to bedside. J Transl Med. 2012, 10: 150-10.1186/1479-5876-10-150.CrossRef
6.
go back to reference Allen DG, Hutchins AM, Hammet F, White DJ, Scurry JP, Tabrizi SN, Garland SM, Armes JE: Genetic aberrations detected by comparative genomic hybridisation in vulvar cancers. Br J Cancer. 2002, 86 (6): 924-928. 10.1038/sj.bjc.6600112.CrossRefPubMedPubMedCentral Allen DG, Hutchins AM, Hammet F, White DJ, Scurry JP, Tabrizi SN, Garland SM, Armes JE: Genetic aberrations detected by comparative genomic hybridisation in vulvar cancers. Br J Cancer. 2002, 86 (6): 924-928. 10.1038/sj.bjc.6600112.CrossRefPubMedPubMedCentral
7.
8.
go back to reference Banyard J, Anand-Apte B, Symons M, Zetter BR: Motility and invasion are differentially modulated by Rho family GTPases. Oncogene. 2000, 19 (4): 580-591. 10.1038/sj.onc.1203338.CrossRefPubMed Banyard J, Anand-Apte B, Symons M, Zetter BR: Motility and invasion are differentially modulated by Rho family GTPases. Oncogene. 2000, 19 (4): 580-591. 10.1038/sj.onc.1203338.CrossRefPubMed
9.
go back to reference Majid S, Dar AA, Saini S, Shahryari V, Arora S, Zaman MS, Chang I, Yamamura S, Chiyomaru T, Fukuhara S, Tanaka Y, Deng G, Tabatabai ZL, Dahiya R: MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer. PLoS One. 2012, 7 (10): e46743-10.1371/journal.pone.0046743.CrossRefPubMedPubMedCentral Majid S, Dar AA, Saini S, Shahryari V, Arora S, Zaman MS, Chang I, Yamamura S, Chiyomaru T, Fukuhara S, Tanaka Y, Deng G, Tabatabai ZL, Dahiya R: MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer. PLoS One. 2012, 7 (10): e46743-10.1371/journal.pone.0046743.CrossRefPubMedPubMedCentral
10.
go back to reference Vigil D, Kim TY, Plachco A, Garton AJ, Castaldo L, Pachter JA, Dong H, Chen X, Tokar B, Campbell SL, Der CJ: ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res. 2012, 72 (20): 5338-5347. 10.1158/0008-5472.CAN-11-2373.CrossRefPubMed Vigil D, Kim TY, Plachco A, Garton AJ, Castaldo L, Pachter JA, Dong H, Chen X, Tokar B, Campbell SL, Der CJ: ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res. 2012, 72 (20): 5338-5347. 10.1158/0008-5472.CAN-11-2373.CrossRefPubMed
11.
go back to reference Zohrabian VM, Forzani B, Chau Z, Murali R, Jhanwar-Uniyal M: Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res. 2009, 29 (1): 119-123.PubMed Zohrabian VM, Forzani B, Chau Z, Murali R, Jhanwar-Uniyal M: Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res. 2009, 29 (1): 119-123.PubMed
12.
go back to reference Liu X, Choy E, Hornicek FJ, Yang S, Yang C, Harmon D, Mankin H, Duan Z: ROCK1 as a potential therapeutic target in osteosarcoma. J Orthop Res. 2011, 29 (8): 1259-1266. 10.1002/jor.21403.CrossRefPubMed Liu X, Choy E, Hornicek FJ, Yang S, Yang C, Harmon D, Mankin H, Duan Z: ROCK1 as a potential therapeutic target in osteosarcoma. J Orthop Res. 2011, 29 (8): 1259-1266. 10.1002/jor.21403.CrossRefPubMed
13.
go back to reference Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP: Rho-Kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun. 2000, 269 (3): 652-659. 10.1006/bbrc.2000.2343.CrossRefPubMed Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP: Rho-Kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun. 2000, 269 (3): 652-659. 10.1006/bbrc.2000.2343.CrossRefPubMed
14.
go back to reference Zhang C, Zhang S, Zhang Z, He J, Xu Y, Liu S: ROCK has a crucial role in regulating prostate tumor growth through interaction with c-Myc. Oncogene. 2013, 1-10. doi:10.1038/onc.2013.505. [Epub ahead of print] Zhang C, Zhang S, Zhang Z, He J, Xu Y, Liu S: ROCK has a crucial role in regulating prostate tumor growth through interaction with c-Myc. Oncogene. 2013, 1-10. doi:10.1038/onc.2013.505. [Epub ahead of print]
15.
go back to reference Lane J, Martin TA, Watkins G, Mansel RE, Jiang WG: The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol. 2008, 33 (3): 585-593.PubMed Lane J, Martin TA, Watkins G, Mansel RE, Jiang WG: The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol. 2008, 33 (3): 585-593.PubMed
16.
go back to reference Ohta T, Takahashi T, Shibuya T, Amita M, Henmi N, Takahashi K, Kurachi H: Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells. Cancer Biol Ther. 2012, 13 (1): 25-33. 10.4161/cbt.13.1.18440.CrossRefPubMed Ohta T, Takahashi T, Shibuya T, Amita M, Henmi N, Takahashi K, Kurachi H: Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells. Cancer Biol Ther. 2012, 13 (1): 25-33. 10.4161/cbt.13.1.18440.CrossRefPubMed
17.
go back to reference Wong CC, Wong CM, Ko FC, Chan LK, Ching YP, Yam JW, Ng IO: Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma. PLoS One. 2008, 3 (7): e2779-10.1371/journal.pone.0002779.CrossRefPubMedPubMedCentral Wong CC, Wong CM, Ko FC, Chan LK, Ching YP, Yam JW, Ng IO: Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma. PLoS One. 2008, 3 (7): e2779-10.1371/journal.pone.0002779.CrossRefPubMedPubMedCentral
18.
go back to reference Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y, Oshima H: Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 2003, 9 (7): 2632-2641.PubMed Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y, Oshima H: Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 2003, 9 (7): 2632-2641.PubMed
19.
go back to reference Guan R, Xu X, Chen M, Hu H, Ge H, Wen S, Zhou S, Pi R: Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors. Eur J Med Chem. 2013, 70: 613-622.CrossRefPubMed Guan R, Xu X, Chen M, Hu H, Ge H, Wen S, Zhou S, Pi R: Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors. Eur J Med Chem. 2013, 70: 613-622.CrossRefPubMed
20.
go back to reference Lock FE, Ryan KR, Poulter NS, Parsons M, Hotchin NA: Differential regulation of adhesion complex turnover by ROCK1 and ROCK2. PLoS One. 2012, 7 (2): e31423-10.1371/journal.pone.0031423.CrossRefPubMedPubMedCentral Lock FE, Ryan KR, Poulter NS, Parsons M, Hotchin NA: Differential regulation of adhesion complex turnover by ROCK1 and ROCK2. PLoS One. 2012, 7 (2): e31423-10.1371/journal.pone.0031423.CrossRefPubMedPubMedCentral
21.
go back to reference Rath N, Olson MF: Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO Rep. 2012, 13 (10): 900-908. 10.1038/embor.2012.127.CrossRefPubMedPubMedCentral Rath N, Olson MF: Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO Rep. 2012, 13 (10): 900-908. 10.1038/embor.2012.127.CrossRefPubMedPubMedCentral
22.
go back to reference Amano M, Nakayama M, Kaibuchi K: Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken). 2010, 67 (9): 545-554. 10.1002/cm.20472.CrossRef Amano M, Nakayama M, Kaibuchi K: Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken). 2010, 67 (9): 545-554. 10.1002/cm.20472.CrossRef
23.
go back to reference Gurkar AU, Chu K, Raj L, Bouley R, Lee SH, Kim YB, Dunn SE, Mandinova A, Lee SW: Identification of ROCK1 kinase as a critical regulator of Beclin1-mediated autophagy during metabolic stress. Nat Commun. 2013, 4: 2189-CrossRefPubMedPubMedCentral Gurkar AU, Chu K, Raj L, Bouley R, Lee SH, Kim YB, Dunn SE, Mandinova A, Lee SW: Identification of ROCK1 kinase as a critical regulator of Beclin1-mediated autophagy during metabolic stress. Nat Commun. 2013, 4: 2189-CrossRefPubMedPubMedCentral
24.
go back to reference Nakashima M, Adachi S, Yasuda I, Yamauchi T, Kawaguchi J, Hanamatsu T, Yoshioka T, Okano Y, Hirose Y, Kozawa O, Moriwaki H: Inhibition of Rho-associated coiled-coil containing protein kinase enhances the activation of epidermal growth factor receptor in pancreatic cancer cells. Mol Cancer. 2011, 10: 79-10.1186/1476-4598-10-79.CrossRefPubMedPubMedCentral Nakashima M, Adachi S, Yasuda I, Yamauchi T, Kawaguchi J, Hanamatsu T, Yoshioka T, Okano Y, Hirose Y, Kozawa O, Moriwaki H: Inhibition of Rho-associated coiled-coil containing protein kinase enhances the activation of epidermal growth factor receptor in pancreatic cancer cells. Mol Cancer. 2011, 10: 79-10.1186/1476-4598-10-79.CrossRefPubMedPubMedCentral
25.
go back to reference Rodrigues IS, Lavorato-Rocha AM, De M, Maia B, Stiepcich MM, De Carvalho FM, Baiocchi G, Soares FA, Rocha RM: Epithelial-mesenchymal transition-like events in vulvar cancer and its relation with HPV. Br J Cancer. 2013, 109 (1): 184-194. 10.1038/bjc.2013.273.CrossRefPubMedPubMedCentral Rodrigues IS, Lavorato-Rocha AM, De M, Maia B, Stiepcich MM, De Carvalho FM, Baiocchi G, Soares FA, Rocha RM: Epithelial-mesenchymal transition-like events in vulvar cancer and its relation with HPV. Br J Cancer. 2013, 109 (1): 184-194. 10.1038/bjc.2013.273.CrossRefPubMedPubMedCentral
26.
27.
go back to reference Diskin SJ, Eck T, Greshock J, Mosse YP, Naylor T, Stoeckert CJ, Weber BL, Maris JM, Grant GR: STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res. 2006, 16: 1149-1158. 10.1101/gr.5076506.CrossRefPubMedPubMedCentral Diskin SJ, Eck T, Greshock J, Mosse YP, Naylor T, Stoeckert CJ, Weber BL, Maris JM, Grant GR: STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res. 2006, 16: 1149-1158. 10.1101/gr.5076506.CrossRefPubMedPubMedCentral
28.
go back to reference Silveira SM, Villacis RAR, Marchi FA, Barros Filho MC, Drigo AS, Scapulatempo Neto C, Lopes A, Cunha IW, Rogatto SR: Genomic signatures predict poor outcome in undifferentiated pleomorphic sarcomas and leiomyosarcomas. PLoS One. 2013, 8 (6): e67643-10.1371/journal.pone.0067643.CrossRefPubMedPubMedCentral Silveira SM, Villacis RAR, Marchi FA, Barros Filho MC, Drigo AS, Scapulatempo Neto C, Lopes A, Cunha IW, Rogatto SR: Genomic signatures predict poor outcome in undifferentiated pleomorphic sarcomas and leiomyosarcomas. PLoS One. 2013, 8 (6): e67643-10.1371/journal.pone.0067643.CrossRefPubMedPubMedCentral
29.
go back to reference De Melo MB, Fontes AM, Lavorato-Rocha AM, Rodrigues IS, De Brot L, Baiocchi G, Stiepcich MM, Soares FA, Rocha RM: EGFR expression in vulvar cancer: clinical implications and tumor heterogeneity. Human Pathol. 2014, 45 (5): 917-925. 10.1016/j.humpath.2014.01.015.CrossRef De Melo MB, Fontes AM, Lavorato-Rocha AM, Rodrigues IS, De Brot L, Baiocchi G, Stiepcich MM, Soares FA, Rocha RM: EGFR expression in vulvar cancer: clinical implications and tumor heterogeneity. Human Pathol. 2014, 45 (5): 917-925. 10.1016/j.humpath.2014.01.015.CrossRef
30.
go back to reference Brustmann H: Epidermal growth factor receptor is involved in the development of an invasive phenotype in vulvar squamous lesions, but is not related to MIB-1 immunoreactivity. Int J Gynecol Pathol. 2007, 26 (4): 481-489. 10.1097/pgp.0b013e3180555999.CrossRefPubMed Brustmann H: Epidermal growth factor receptor is involved in the development of an invasive phenotype in vulvar squamous lesions, but is not related to MIB-1 immunoreactivity. Int J Gynecol Pathol. 2007, 26 (4): 481-489. 10.1097/pgp.0b013e3180555999.CrossRefPubMed
31.
go back to reference Mali RS, Ramdas B, Ma P, Shi J, Munugalavadla V, Sims E, Wei L, Vemula S, Nabinger SC, Goodwin CB, Chan RJ, Traina F, Visconte V, Tiu RV, Lewis TA, Stern AM, Wen Q, Crispino JD, Boswell HS, Kapur R: Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Cancer Cell. 2011, 20 (3): 357-369. 10.1016/j.ccr.2011.07.016.CrossRefPubMedPubMedCentral Mali RS, Ramdas B, Ma P, Shi J, Munugalavadla V, Sims E, Wei L, Vemula S, Nabinger SC, Goodwin CB, Chan RJ, Traina F, Visconte V, Tiu RV, Lewis TA, Stern AM, Wen Q, Crispino JD, Boswell HS, Kapur R: Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Cancer Cell. 2011, 20 (3): 357-369. 10.1016/j.ccr.2011.07.016.CrossRefPubMedPubMedCentral
32.
go back to reference Sahai E, Olson MF, Marshall CJ: Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J. 2001, 20 (4): 755-766. 10.1093/emboj/20.4.755.CrossRefPubMedPubMedCentral Sahai E, Olson MF, Marshall CJ: Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J. 2001, 20 (4): 755-766. 10.1093/emboj/20.4.755.CrossRefPubMedPubMedCentral
33.
go back to reference Hosono Y, Yamaguchi T, Mizutani E, Yanagisawa K, Arima C, Tomida S, Shimada Y, Hiraoka M, Kato S, Yokoi K, Suzuki M, Takahashi T: MYBPH, a transcriptional target of TTF-1, inhibits ROCK1, and reduces cell motility and metastasis. EMBO J. 2012, 31 (2): 481-493. 10.1038/emboj.2011.416.CrossRefPubMed Hosono Y, Yamaguchi T, Mizutani E, Yanagisawa K, Arima C, Tomida S, Shimada Y, Hiraoka M, Kato S, Yokoi K, Suzuki M, Takahashi T: MYBPH, a transcriptional target of TTF-1, inhibits ROCK1, and reduces cell motility and metastasis. EMBO J. 2012, 31 (2): 481-493. 10.1038/emboj.2011.416.CrossRefPubMed
34.
go back to reference Li G, Liu L, Shan C, Cheng Q, Budhraja A, Zhou T, Cui H, Gao N: RhoA/ROCK/PTEN signaling is involved in AT-101-mediated apoptosis in human leukemia cells in vitro and in vivo. Cell Death Dis. 2014, 5: e998-10.1038/cddis.2013.519.CrossRefPubMedPubMedCentral Li G, Liu L, Shan C, Cheng Q, Budhraja A, Zhou T, Cui H, Gao N: RhoA/ROCK/PTEN signaling is involved in AT-101-mediated apoptosis in human leukemia cells in vitro and in vivo. Cell Death Dis. 2014, 5: e998-10.1038/cddis.2013.519.CrossRefPubMedPubMedCentral
35.
go back to reference Li GB, Chenq Q, Liu L, Zhou T, Shan CY, Hu XY, Zhou J, Liu EH, Li P, Gao N: Mitochondrial translocation of cofilin is required for allyl isothiocyanate-mediated cell death via ROCK1/PTEN/PI3K signaling pathway. Cell Commun Signal. 2013, 11: 50-10.1186/1478-811X-11-50.CrossRefPubMedPubMedCentral Li GB, Chenq Q, Liu L, Zhou T, Shan CY, Hu XY, Zhou J, Liu EH, Li P, Gao N: Mitochondrial translocation of cofilin is required for allyl isothiocyanate-mediated cell death via ROCK1/PTEN/PI3K signaling pathway. Cell Commun Signal. 2013, 11: 50-10.1186/1478-811X-11-50.CrossRefPubMedPubMedCentral
36.
go back to reference Keniry M, Parsons R: The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene. 2008, 27: 5477-5485. 10.1038/onc.2008.248.CrossRefPubMed Keniry M, Parsons R: The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene. 2008, 27: 5477-5485. 10.1038/onc.2008.248.CrossRefPubMed
37.
go back to reference Sahai E, Marshall CJ: Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol. 2003, 5 (8): 711-719. 10.1038/ncb1019.CrossRefPubMed Sahai E, Marshall CJ: Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol. 2003, 5 (8): 711-719. 10.1038/ncb1019.CrossRefPubMed
38.
go back to reference Nakayama M, Amano M, Katsumi A, Kaneko T, Kawabata S, Takefuji M, Kaibuchi K: Rho-kinase and myosin II activities are required for cell type and environment specific migration. Genes Cells. 2005, 10 (2): 107-117. 10.1111/j.1365-2443.2005.00823.x.CrossRefPubMed Nakayama M, Amano M, Katsumi A, Kaneko T, Kawabata S, Takefuji M, Kaibuchi K: Rho-kinase and myosin II activities are required for cell type and environment specific migration. Genes Cells. 2005, 10 (2): 107-117. 10.1111/j.1365-2443.2005.00823.x.CrossRefPubMed
39.
go back to reference Hacker NF, Berek JS, Lagasse LD, Leuchter RS, Moore JG: Management of Regional Lymph Nodes and Their Prognostic Influence in Vulvar Cancer. Obstet Gynecol. 1983, 61 (4): 408-412.PubMed Hacker NF, Berek JS, Lagasse LD, Leuchter RS, Moore JG: Management of Regional Lymph Nodes and Their Prognostic Influence in Vulvar Cancer. Obstet Gynecol. 1983, 61 (4): 408-412.PubMed
40.
go back to reference Shi J, Wei L: Rho kinase in the regulation of cell death and survival. Arch Immunol Ther Exp. 2007, 55 (2): 61-75. 10.1007/s00005-007-0009-7.CrossRef Shi J, Wei L: Rho kinase in the regulation of cell death and survival. Arch Immunol Ther Exp. 2007, 55 (2): 61-75. 10.1007/s00005-007-0009-7.CrossRef
41.
go back to reference Orlando KA, Stone NL, Pittman RN: Rho kinase regulates fragmentation and phagocytosis of apoptotic cells. Exp Cell Res. 2006, 312 (1): 5-15. 10.1016/j.yexcr.2005.09.012.CrossRefPubMed Orlando KA, Stone NL, Pittman RN: Rho kinase regulates fragmentation and phagocytosis of apoptotic cells. Exp Cell Res. 2006, 312 (1): 5-15. 10.1016/j.yexcr.2005.09.012.CrossRefPubMed
42.
go back to reference Tanaka F, Kawano Y, Li M, Takata T, Miyahara R, Yanagihara K, Ohtake Y, Fukuse T, Wada H: Prognostic significance of apoptotic index in completely resected non-small-cell lung cancer. J Clin Oncol. 1999, 17 (9): 2728-2736.PubMed Tanaka F, Kawano Y, Li M, Takata T, Miyahara R, Yanagihara K, Ohtake Y, Fukuse T, Wada H: Prognostic significance of apoptotic index in completely resected non-small-cell lung cancer. J Clin Oncol. 1999, 17 (9): 2728-2736.PubMed
43.
go back to reference Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S: Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res. 2002, 62 (21): 6240-6245.PubMed Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S: Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res. 2002, 62 (21): 6240-6245.PubMed
44.
go back to reference Kroiss A, Vincent S, Decaussin-Petrucci M, Meugnier E, Viallet J, Ruffion A, Chalmel F, Samarut J, Allioli N: Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2. Oncogene. 2014, doi:10.1038/onc.2014.222. [Epub ahead of print] Kroiss A, Vincent S, Decaussin-Petrucci M, Meugnier E, Viallet J, Ruffion A, Chalmel F, Samarut J, Allioli N: Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2. Oncogene. 2014, doi:10.1038/onc.2014.222. [Epub ahead of print]
45.
go back to reference Shin JY, Kim YI, Cho SJ, Lee MK, Kook MC, Lee JH, Lee SS, Ashktorab H, Smooy DT, Ryu KW, Kim YW, Chhoi IJ: MicroRNA 135a suppresses lymph node metastasis through down-regulation of ROCK1 in early gastric cancer. PLoS One. 2014, 9 (1): e85205-10.1371/journal.pone.0085205.CrossRefPubMedPubMedCentral Shin JY, Kim YI, Cho SJ, Lee MK, Kook MC, Lee JH, Lee SS, Ashktorab H, Smooy DT, Ryu KW, Kim YW, Chhoi IJ: MicroRNA 135a suppresses lymph node metastasis through down-regulation of ROCK1 in early gastric cancer. PLoS One. 2014, 9 (1): e85205-10.1371/journal.pone.0085205.CrossRefPubMedPubMedCentral
46.
go back to reference Xu X, Li S, Lin Y, Chen H, Hu Z, Mao Y, Xu X, Wu J, Zhu Y, Zheng X, Luo J, Xie L: MicroRNA 124-3p inhibits cell migration and invasion in bladdes cancer cells by targeting ROCK1. J Trans Med. 2013, 11: 276-10.1186/1479-5876-11-276.CrossRef Xu X, Li S, Lin Y, Chen H, Hu Z, Mao Y, Xu X, Wu J, Zhu Y, Zheng X, Luo J, Xie L: MicroRNA 124-3p inhibits cell migration and invasion in bladdes cancer cells by targeting ROCK1. J Trans Med. 2013, 11: 276-10.1186/1479-5876-11-276.CrossRef
Metadata
Title
ROCK1 as a novel prognostic marker in vulvar cancer
Authors
Erica M Akagi
André M Lavorato-Rocha
Beatriz de Melo Maia
Iara S Rodrigues
Kátia C Carvalho
Monica M Stiepcich
Glauco Baiocchi
Yukie Sato-Kuwabara
Silvia R Rogatto
Fernando A Soares
Rafael M Rocha
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-822

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine